enVVeno Corp (NVNO) Enterprise Value to EBITDA Ratio

Public company logo of envveno.com (NVNO)

The prospects for enVVeno Medical (NVNO) rely on obtaining US regulatory approvals to bring its valveless implant to market, with existing funds sufficient for a secure launch. The company is acting as a pioneer, having developed a unique venous valve bioprosthesis to combat venous insufficiency. This price trend visualization on GURU.Markets with the 0.00 metric confirms resilient demand for minimally invasive solutions, ensuring stable sales growth.

enVVeno Medical Corporation - NVNO Company Value to EBITDA (period 11/23/2025 - 11/15/2026)

Comprehensive metric breakdowns and analytics for enVVeno Medical Corporation (NVNO)

- current price and projected stock value:
Stock Price envveno.com|NVNO - Analyst Median Target
- market capitalization details:
Market Valuation enVVeno Medical|NVNO - Full Business Value
- business book valuation details:
Book Value per Share enVVeno Medical|NVNO - Total Stockholders' Equity|Market Capitalization to Book Value Ratio envveno.com|NVNO - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio enVVeno Medical|NVNO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity enVVeno Corp|NVNO - Company Total Debt|Debts to Book Capitalization enVVeno Corp|NVNO - Long-Term Debt|Company Short-Term Debts enVVeno Medical|Quick Ratio envveno.com
- financial results and valuation multiples details:
NVNO - Net Financial Result|Projected Future Earnings enVVeno Medical|NVNO - Price to Earnings Ratio|Forward P/E Multiple envveno.com|NVNO - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization enVVeno Medical Corp.|NVNO - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months enVVeno Medical|NVNO - Earnings per share for the trailing year|Quarterly EPS earnings growth envveno.com|NVNO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year enVVeno Medical
- revenue and sales details:
NVNO - Company Total Sales Volume|Company Future Sales Volume enVVeno Corp|NVNO - P/S Multiple|Forward P/S Multiple enVVeno|NVNO - Annual Revenue Growth (Last Twelve Months)
Analysis of all company metrics:enVVeno Medical Corporation NVNO
Manufactured products of enVVeno Medical Corp.

For the stable venous implant manufacturing business of enVVeno Medical (NVNO), the EV/EBITDA multiple serves as a key indicator of investment attractiveness. This metric compares the total enterprise value (equity plus net debt) with operating profit before depreciation and amortization, allowing for an assessment of the real value of assets relative to their ability to generate cash flow, regardless of the tax regime or debt structure.

Competitor analysis

Boston Scientific Inc - Enterprise Value to EBITDA Ratio|Edwards Lifesciences (EW) - Company Value to EBITDA|ResMed Corporation - EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio PODD|ZBH: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation COO|ALGN (Align Technology) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation GMED (Globus Medical)|Enterprise Value to EBITDA Ratio TMDX (TransMedics Group, Inc.)|ATEC (Alphatec Holdings) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artivion Corp AORT|ENOV - Enterprise Value to EBITDA Ratio|Integra LifeSciences Corp - EV/EBITDA Multiple|Company Value to EBITDA Establishment Labs|BBNX: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation IRMD|EMBC (Embecta Health) - EV/EBITDA Multiple|Tandem Diabetes (TNDM) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AXGN|Enterprise Value to EBITDA Ratio SI-BONE, Inc. SIBN|EV/EBITDA Multiple OFIX (orthofix.com)|Bioventus Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|KIDS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TMCI: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SRTA (Strata Critical Medical Inc) - Enterprise Value to EBITDA Ratio|Carlsmed Inc - Business Value to Operating Income Before Depreciation|RXST (RxSight Ophthalmic) - EV/EBITDA Multiple|Company Value to EBITDA clearpointneuro.com CLPT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Stereotaxis Inc (STXS)|Neuronetics, Inc. (STIM) - Enterprise Value to EBITDA Multiple|Sight Sciences Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Orchestra BioMed, Inc. OBIO|Anika Therapeutics Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio InspireMD Inc NSPR|Jin Medical (ZJYL) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VANI (Vivani)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization xtantmedical.com|Enterprise Value to EBITDA Ratio NeuroOne Medical Technologies (NMTC)|EV/EBITDA Multiple MODD|Myomo, Inc - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Envoy Medical, Inc. COCH|VVOS: Enterprise Value to Operating Income Before Depreciation|SINT: Enterprise Value to EBITDA Ratio|Tenon Medical - Enterprise Value to Operating Income Before Depreciation Ratio|Lifeward (LFWD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Autonomix Medical, Inc. (AMIX) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio IVF|Company Value to EBITDA Bone Biologics Inc BBLG|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Axonics Inc. (AXNX)|BIOL - Company Value to EBITDA|EV/EBITDA Multiple DYNT (Dynatronics Corp)|Enterprise Value to EBITDA Multiple Paragon 28, Inc.|INVO: Enterprise Value to EBITDA Ratio